A Phase 3 interventional study of Doxorubicin 20 mg/m2 and Doxorubicin 30 mg/m2 in Carcinoma, Hepatocellular, sponsored by Valerio Therapeutics. Completed at 70 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.
Sponsored by Valerio Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing doxorubicin in Carcinoma, Hepatocellular — none open to participants now, 2 under way, 1 of them phase 3. Doxorubicin · Carcinoma, Hepatocellular.
Among the 26 studies testing doxorubicin in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 3, and was the 19th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 26 studies testing doxorubicin in Carcinoma, Hepatocellular is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 8
First in 1994; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 397 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 44 across the 24 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 26 have an industry lead sponsor. The 10 most frequent:
Valerio Therapeutics is the lead sponsor of 25 studies on the registry; none are open to participants now.
Valerio Therapeutics has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
2 of the studies testing doxorubicin in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT01840592Memorial Sloan Kettering Cancer CenterSorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies testing doxorubicin in Carcinoma, Hepatocellular, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib. Patients with HCC with or without cirrhosis and with good liver functions are eligible. Only those who can not benefit from treatment for which efficacy is demonstrated are eligible.
These patients are usually proposed either best standard of care (BSC) or participation to clinical trials. Patients eligible for the RELIVE study will receive either DT at 20 mg/m2 or DT at 30 mg/m2 or the BSC.
Doxorubicin-Transdrug™ (DT) is a nanoparticle formulation of doxorubicin.In in vitro and in vivo models, DT was shown to overcome the multidrug resistance (MDR) and to be more effective than doxorubicin on both sensitive and resistant tumour models and in particular in the X/myc bi-transgenic MDR murine model of HCC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with:
HCC diagnosed according to the American Association for Study of Liver Diseases (AASLD) and/or European Association for the Study of the Liver (EASL) criteria:
If appearance not typical for HCC on initial imaging: second contrast enhanced study (CT or MRI) showing typical appearances for HCC defined as arterial enhancement and rapid wash-out in portal venous or delayed phase;
Laboratory tests as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
Drug: Doxorubicin 20 mg/m2
DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
Drug: Doxorubicin 30 mg/m2
Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
Drug: Best Standard of Care
Drug page: Doxorubicin
Also known as: Doxorubicin Transdrug (DT) at 20 mg/m2
Drug page: Doxorubicin
Also known as: Doxorubicin Transdrug (DT) at 30 mg/m2
Also known as: BSC
Overall Survival (OS)
OS is defined as the time from date of randomization to the date of death from any cause.
Time frame: Time from date of randomization to the date of death from any cause with initial assessment up to 24 months and follow-up assessment up to 45 months.
Progression-free Survival (PFS)
PFS is defined as time from the date of randomisation to the date of the first documented progression or death from any cause. PFS determined by independent radiological review according to Response Evaluation Criteria In Solid Tumour (RECIST) 1.1 is determine by at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.
Time frame: Time from date of randomization to date of first documented progression or death from any cause, which ever came first, assessed up to 20 months.
Objective Response Rate (ORR)
ORR is defined as percent of patients whose best overall response is complete response (CR) or partial response (PR) during the study treatment period and based on the evaluation of independent radiological review according to RECIST 1.1 for target lesions and assessed by MRI: CR is disappearance of all targets extra nodal lesions and the regression of all nodal lesions to \< 10 mm; PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. PD is at least a 20% increase in the sum of diameters of target lesions, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.
Time frame: Time from date of first treatment cycle to date of last cycle of treatment for the full duration of study treatment up to 24 months.
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) Considered Related to Treatment Categorized by Severity, Withdrawal From Study, or Death
The number of participants experiencing TEAEs considered related to treatment and categorized by severity of all related TEAEs according to National Cancer Institute/Common Toxicity Criteria (NCI-CTCAE) v4.0 and resulting in patient withdrawal from study or death.
Time frame: Time from date of initial treatment to date of death, disease progression, or participant withdrawal from the study.
Number of Participants With Cardiovascular and Respiratory Events Related to Study Drug
The number of participants with cardiovascular and respiratory adverse events (AEs) were assessed according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, using the Medical Dictionary for Regulatory Activities (MedDRA). The AE numbers reported are those considered related to treatment. Related AEs are those that are judged unlikely, possibly, probably or definitely related to the study or study drug by the investigator.
Time frame: Time from date of initial treatment to date of death, disease progression, or patient withdrawal from the study.
Number of Participants Experiencing a Reduction of Oxygen Saturation (SaO2) During and After Doxorubicin Transdrug (DT) Infusion
Number of participants experiencing an SaO2 reduction defined as a decrease =\< 90% during or after DT infusion until resolution to =\>93%. Participants had continuous monitoring of SaO2 saturation with pulse oximeter during 6 hour infusion and up to 24 hour after infusion start. SaO2 measures the amount of oxygen (in percent) bound to hemoglobin in red blood cells. SaO2 saturation was only monitored and reported in the DT infusion group. Reduction in SaO2 could result in modify DT dosing regimen. Decreases in SaO2 are a known and expected occurrence with DT infusions, and close monitoring of SaO2 was specified by the protocol to protect patients from potential respiratory distress during infusions.
Time frame: Time from start of infusion to resolution of reduction in oxygen saturation.
Number of Participants With Clinically Significant Abnormal Change in Respiratory Function
Number of participants with any clinically significant abnormal change in respiratory function test over the study to include carbon monoxide diffusing capacity to measure lung function, forced expiratory volume in 1 second to measure ability to expel air from your lungs, total lung capacity to measure total amount of air in the lungs after taking the deepest breath possible, and vital capacity to measure the greatest volume of air that can be expelled from the lungs after taking the deepest breath possible. Clinically significant abnormal changes in respiratory function was determined by the investigator.
Time frame: Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.
Number of Participants Experiencing Clinically Significant Abnormal Electrocardiogram (ECG) Changes From Baseline
Number of participants experiencing clinically significant abnormal ECG changes from baseline over the course of the study. ECG were completed every month before each infusion. ECG will detect changes in heart rhythm. Clinically significant abnormal changes in ECG were determined by the investigator.
Time frame: Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.
Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event
Number of participants that experienced a change from baseline in LVEF with severity of LVEF noted as follows: Normal: 100 - 50%, 0 - 9% drop from baseline resting ejection fraction (EF), Grade 2 = 50 - 40%, 10 - 19% drop from baseline resting EF; Grade 3 = 39 - 20%, \>20% drop from baseline; Grade 4 = \<20%. LVEF was monitored every other month. LVEF measures how much blood the left ventricle of the heart pumps out with each contraction and is used to assess the severity of left ventricle dysfunction in the heart. Clinical significance changes were determined by the investigator.
Time frame: Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.
A total of 541 patients were screened, and 397 patients were randomized a 1:1:1 allocation at 69 sites in 11 countries worldwide. The randomization was performed using an interactive web response system (IWRS) with stratification based on region. Enrollment of first patient was June 15, 2012. Data cutoff was May 28, 2017 (24 months) for initial study and May 10, 2019, for follow-up period (45 months).
| Milestone | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care |
|---|---|---|---|
| Started | 130 | 133 | 134 |
| Completed | 4 | 7 | 4 |
| Not completed | 126 | 126 | 130 |
| Withdrew: Progression of disease | 92 | 76 | 58 |
| Withdrew: Death | 8 | 9 | 12 |
| Withdrew: Serious adverse event | 3 | 15 | 11 |
| Withdrew: Withdrawal by subject | 3 | 2 | 20 |
| Withdrew: Adverse event | 3 | 11 | 3 |
| Withdrew: Aggravation of liver dysfunction | 5 | 4 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 7 |
| Withdrew: No respect of criteria for continuing treatment | 1 | 3 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Screening failure | 1 | 0 | 0 |
| Withdrew: Other | 8 | 6 | 15 |
OS is defined as the time from date of randomization to the date of death from any cause.
| months | Doxorubicin Transdrug (DT) 20 mg/m2 Group | Doxorubicin Transdrug at 30 mg/m2 | Doxorubicin Transdrug Pooled | Best Standard of Care (BSC) |
|---|---|---|---|---|
| OS up to 24 Months | 10.1 (7.3 to 11.4) | 8.9 (7.0 to 10.3) | 9.1 (8.1 to 10.4) | 9.0 (7.1 to 11.8) |
| OS up to 45 Months | 9.8 (7.4 to 11.2) | 8.8 (7.1 to 10.3) | 8.9 (8.1 to 10.3) | 9.0 (7.2 to 11.8) |
PFS is defined as time from the date of randomisation to the date of the first documented progression or death from any cause. PFS determined by independent radiological review according to Response Evaluation Criteria In Solid Tumour (RECIST) 1.1 is determine by at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.
| months | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Doxorubicin Transdrug Pooled | Best Standard of Care |
|---|---|---|---|---|
| Progression-free Survival (PFS) | 2.3 (2.0 to 2.8) | 2.3 (2.1 to 2.6) | 2.3 (2.1 to 2.6) | 2.3 (2.1 to 2.8) |
ORR is defined as percent of patients whose best overall response is complete response (CR) or partial response (PR) during the study treatment period and based on the evaluation of independent radiological review according to RECIST 1.1 for target lesions and assessed by MRI: CR is disappearance of all targets extra nodal lesions and the regression of all nodal lesions to \< 10 mm; PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. PD is at least a 20% increase in the sum of diameters of target lesions, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.
| Participants | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Doxorubicin Transdrug Pooled | Best Standard of Care |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 2 | 2 | 1 |
| Stable Disease | 39 | 41 | 80 | 31 |
| Progressive Disease | 58 | 63 | 121 | 40 |
| Not Evaluable | 33 | 27 | 60 | 62 |
The number of participants experiencing TEAEs considered related to treatment and categorized by severity of all related TEAEs according to National Cancer Institute/Common Toxicity Criteria (NCI-CTCAE) v4.0 and resulting in patient withdrawal from study or death.
| Participants | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care (BSC) |
|---|---|---|---|
| TEAEs | 79 | 98 | 58 |
| Severe TEAEs | 26 | 46 | 31 |
| Serious TEAEs | 13 | 18 | 13 |
| TEAEs Leading to Withdrawal | 5 | 9 | 9 |
| TEAEs Leading to Death | 1 | 2 | 1 |
The number of participants with cardiovascular and respiratory adverse events (AEs) were assessed according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, using the Medical Dictionary for Regulatory Activities (MedDRA). The AE numbers reported are those considered related to treatment. Related AEs are those that are judged unlikely, possibly, probably or definitely related to the study or study drug by the investigator.
| Participants | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care (BSC) |
|---|---|---|---|
| Cardiac Disorders | 4 | 5 | 1 |
| Vascular Disorders | 8 | 8 | 6 |
| Blood Pressure Increased | 0 | 1 | 0 |
| Respiratory, Thoracic, and Mediastinal Disorders | 17 | 20 | 13 |
| Oxygen Saturation Decreased | 2 | 7 | 1 |
| Respiratory Rate Increased | 2 | 5 | 0 |
| Respiratory Rate Decreased | 1 | 1 | 0 |
| Ejection Fraction Decreased | 1 | 0 | 0 |
Number of participants experiencing an SaO2 reduction defined as a decrease =\< 90% during or after DT infusion until resolution to =\>93%. Participants had continuous monitoring of SaO2 saturation with pulse oximeter during 6 hour infusion and up to 24 hour after infusion start. SaO2 measures the amount of oxygen (in percent) bound to hemoglobin in red blood cells. SaO2 saturation was only monitored and reported in the DT infusion group. Reduction in SaO2 could result in modify DT dosing regimen. Decreases in SaO2 are a known and expected occurrence with DT infusions, and close monitoring of SaO2 was specified by the protocol to protect patients from potential respiratory distress during infusions.
| Participants | Doxorubicin Transdrug (DT) 20 mg/m2 | Doxorubicin Transdrug 30 mg/m2 |
|---|---|---|
| Number of Participants Experiencing a Reduction of Oxygen Saturation (SaO2) During and After Doxorubicin Transdrug (DT) Infusion | 2 | 4 |
Number of participants with any clinically significant abnormal change in respiratory function test over the study to include carbon monoxide diffusing capacity to measure lung function, forced expiratory volume in 1 second to measure ability to expel air from your lungs, total lung capacity to measure total amount of air in the lungs after taking the deepest breath possible, and vital capacity to measure the greatest volume of air that can be expelled from the lungs after taking the deepest breath possible. Clinically significant abnormal changes in respiratory function was determined by the investigator.
| Participants | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care (BSC) |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Change in Respiratory Function | 13 | 8 | 0 |
Number of participants experiencing clinically significant abnormal ECG changes from baseline over the course of the study. ECG were completed every month before each infusion. ECG will detect changes in heart rhythm. Clinically significant abnormal changes in ECG were determined by the investigator.
| Participants | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care (BSC) |
|---|---|---|---|
| Number of Participants Experiencing Clinically Significant Abnormal Electrocardiogram (ECG) Changes From Baseline | 4 | 6 | 5 |
Number of participants that experienced a change from baseline in LVEF with severity of LVEF noted as follows: Normal: 100 - 50%, 0 - 9% drop from baseline resting ejection fraction (EF), Grade 2 = 50 - 40%, 10 - 19% drop from baseline resting EF; Grade 3 = 39 - 20%, \>20% drop from baseline; Grade 4 = \<20%. LVEF was monitored every other month. LVEF measures how much blood the left ventricle of the heart pumps out with each contraction and is used to assess the severity of left ventricle dysfunction in the heart. Clinical significance changes were determined by the investigator.
| Participants | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care (BSC) |
|---|---|---|---|
| At Least One Abnormal Value | 1 | 4 | 2 |
| At Least One Grade 3-4 Value | 1 | 1 | 1 |
Collected over Adverse events (AEs) were collected until 1 month after last treatment. Treatment continued until patient experienced disease progression, aggravation of liver dysfunction, death, serious AE (SAE), or intolerable AE; or the patient withdrew consent or was withdrawn from study by investigator for reasons listed in the protocol. Median treatment durations were 1.9, 2.7, and 2.4 months in the Doxorubicin Transdrug (DT) 20 mg/m2, DT 30 mg/m2, and best standard of care (BSC) groups, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxorubicin Transdrug (DT) at 20 mg/m2 | 118/122 (96.7%) | 37/122 (30.3%) | 110/122 (90.2%) |
| Doxorubicin Transdrug at 30 mg/m2 | 119/120 (99.2%) | 37/120 (30.8%) | 112/120 (93.3%) |
| Best Standard of Care | 113/134 (84.3%) | 48/134 (35.8%) | 97/134 (72.4%) |
| Event | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care |
|---|---|---|---|
| General physical health deteriorationGeneral disorders | 3/122 | 2/120 | 8/134 |
| Hepatic encephalopathyHepatobiliary disorders | 1/122 | 5/120 | 7/134 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/122 | 3/120 | 7/134 |
| AnaemiaBlood and lymphatic system disorders | 1/122 | 1/120 | 4/134 |
| FatigueGeneral disorders | 0/122 | 3/120 | 0/134 |
| Catheter site infectionInfections and infestations | 3/122 | 0/120 | 2/134 |
| AscitesGastrointestinal disorders | 3/122 | 1/120 | 3/134 |
| Abdominal painGastrointestinal disorders | 3/122 | 0/120 | 1/134 |
| DysphagiaGastrointestinal disorders | 3/122 | 0/120 | 1/134 |
| Acute kidney injuryRenal and urinary disorders | 0/122 | 0/120 | 3/134 |
| Event | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care |
|---|---|---|---|
| AstheniaGeneral disorders | 41/122 | 57/120 | 39/134 |
| NauseaGastrointestinal disorders | 26/122 | 33/120 | 24/134 |
| Oedema peripheralGeneral disorders | 9/122 | 25/120 | 24/134 |
| PyrexiaGeneral disorders | 9/122 | 23/120 | 8/134 |
| DiarrhoeaGastrointestinal disorders | 21/122 | 23/120 | 20/134 |
| AnaemiaBlood and lymphatic system disorders | 15/122 | 22/120 | 22/134 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/122 | 14/120 | 24/134 |
| VomitingGastrointestinal disorders | 15/122 | 20/120 | 10/134 |
| Decreased AppetiteMetabolism and nutrition disorders | 16/122 | 19/120 | 21/134 |
| NeutropeniaBlood and lymphatic system disorders | 4/122 | 18/120 | 7/134 |
Intent-to-Treat population: all randomized patients.
| Age, Categorical(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 50 | 62 | 57 | 169 |
| >=65 years | 80 | 71 | 77 | 228 |
| Sex: Female, Male(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| Female | 12 | 27 | 18 | 57 |
| Male | 118 | 106 | 116 | 340 |
| Race/Ethnicity, Customized(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| White | 120 | 119 | 125 | 364 |
| Black | 1 | 3 | 2 | 6 |
| Asian | 1 | 3 | 2 | 6 |
| Other | 1 | 3 | 3 | 7 |
| Hispanic or Latino | 0 | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| North African | 6 | 2 | 0 | 8 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Unknown | 1 | 1 | 1 | 3 |
| Region of Enrollment(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| United States | 2 | 2 | 3 | 7 |
| Europe | 118 | 120 | 119 | 357 |
| Middle East | 10 | 11 | 12 | 33 |
| Alcohol Consumption(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| No Significant Alcohol Consumption | 119 | 127 | 123 | 369 |
| Active Alcohol Consumption | 11 | 6 | 11 | 28 |
| Child Pugh Class(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| Child Pugh A | 114 | 109 | 113 | 336 |
| Child Pugh B | 15 | 24 | 21 | 60 |
| Child Pugh C | 1 | 0 | 0 | 1 |
| Previous Hepatocellular Carcinoma (HCC) Treatments(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| Surgery/Resection | 41 | 49 | 40 | 130 |
| Loco-regional Treatment | 84 | 84 | 84 | 252 |
| Radiotherapy | 14 | 14 | 9 | 37 |
| Sorafenib | 130 | 133 | 134 | 397 |
| Other Systemic Anticancer Therapy | 68 | 73 | 80 | 221 |
| Medical History Active(Participants) | Doxorubicin Transdrug (DT) at 20 mg/m2 | Doxorubicin Transdrug at 30 mg/m2 | Best Standard of Care | Total |
|---|---|---|---|---|
| Hypertension | 73 | 82 | 84 | 239 |
| Type 2 Diabetes Mellitus | 28 | 15 | 35 | 78 |
| Diabetes Mellitus | 17 | 26 | 17 | 60 |
| Hypercholestrolaemia | 12 | 14 | 9 | 35 |
| Varices Oesophageal | 14 | 24 | 15 | 53 |
| Chronic Obstructive Pulmonary Disease | 13 | 8 | 9 | 30 |
| Thrombocytopenia | 7 | 15 | 8 | 30 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2012 to primary completion in May 2017, 59 months.
Results were first posted in Jun 2021, 4 years 1 month after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 59 months is above that.
Counting every sponsor, half of 138 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin